Some antiphospholipid antibodies bind to various serine proteases in hemostasis and tip the balance toward hypercoagulant states

Abstract

The body has an elaborate system that maintains blood circulation and rapidly stops bleeding when vessels are damaged. Abnormalities that disrupt this balance may lead to thrombosis. While β₂-glycoprotein I is generally accepted as the major antigen for antiphospholipid antibodies in the antiphospholipid syndrome, our accumulated studies show that some antiphospholipid antibodies bind homologous enzymatic domains of several serine proteases involved in hemostasis and fibrinolysis. Functionally, some of the protease-reactive antiphospholipid antibodies hinder anticoagulant regulation and resolution of clots, thus tip the balance toward thrombosis. Intriguingly, several serine protease-reactive antiphospholipid antibodies also react with β₂-glycoprotein I, and interactions between antiphospholipid antibodies and antigens are cross-inhibited, indicating that these antiphospholipid antibodies recognize conformational epitope(s) on β₂-glycoprotein I and target serine proteases. Viewed as a whole, these results extend previous reports that antiphospholipid antibodies bind to various hemostasis factors, and provide a new perspective about some antiphospholipid antibodies in terms of their binding specificities and related functional properties in promoting thrombosis.

Keywords

antiphospholipid syndrome β2GPI coagulation fibrinolysis serine proteases

Get full access to this article

View all access options for this article.

References

Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-1632.

Bugge T. , Flick M. , Daugherty C. , Degen J. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.

Pierangeli SS , Chen PP , Raschi E. , et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-250.

Marciniak E. , Romond EH Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432.

Escolar G. , Font J. , Reverter JC , et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Arterioscler Thromb 1992; 12: 196-200.

Zhu M. , Olee T. , Le DT , et al. Characterization of IgG monoclonal anti-cardiolipin/antiβ2GP1 antibodies from two patients with the anti-phospholipid syndrome reveals three species of antibodies. Br J Haematol 1999; 105: 102-109.

Pierangeli SS , Liu XW , Espinola R. , et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84: 388-395.

Rao LVM , Hoang AD , Rapaport SI Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88: 4173-4182.

Zhao Y. , Rumold R. , Ahmed AE , et al. An IgG anti-prothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 1999; 42: 2132-2138.

10.

Vega-Ostertag M. , Liu X. , Kwan-Ki H. , et al. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006; 135: 214-219.

11.

Hwang K. , Grossman J. , Visvanathan S. , et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin . J Immunol 2001; 167: 7192-7198.

12.

Hwang KK , Yang CD , Yan W. , et al. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48: 1622-1630.

13.

Yang CD , Hwang KK , Yan W. , et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765-5773.

14.

Kolev K. , Gombas J. , Varadi B. , et al. Immunoglobulin g from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002; 87: 502-508.

15.

Lu CS , Horizon AA , Hwang KK , et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005; 52: 4018-4027.

16.

Yang YH , Chien D. , Wu M. , et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009; 182: 1674-1680.

17.

Cugno M. , Cabibbe M. , Galli M. , et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103: 2121-2126.

18.

Lin WS , Chen PC , Yang CD , et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta(2)-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007; 56: 1638-1647.